Ramosetron, low dose midazolam, and their combination for the prevention of postoperative nausea and vomiting in patients undergoing thyroidectomy
In patients undergoing thyroidectomy, which is more effective for the prevention of postoperative nausea and vomiting among ramosetron, low dose midazolam, and their combination?
Astellas pharma korea, INC.
69 participants
Aug 1, 2012
Interventional
Conditions
Summary
Postoperative nausea and vomiting (PONV) frequently develops in patients undergoing thyroidectomy, The present study was undertaken to compare the effects of ramosetron, low dose midazolam, and their combination on PONV in patients following total thyroidectomy. Patients were randomly assigned to one of three groups to receive antiemetics as follows: ramosetron 0.3 mg, low dose nidazolam 75microg/kg, or their combination. PONV, postoperative pain intensity, rescue antiemetics requirement, and side effects were assessed at 0, 6, 12, 24h postoperatively.
Eligibility
Inclusion Criteria1
- patients undergoing thyroidectimy
Exclusion Criteria1
- severe impairment of bowel motility, insulin-dependent diabetes mellitus, pregnancy or breast feeding, administration of antiemetic medication within 24 h before operation, history of cardiovascular or respiratory disease, active alcohol or drug usage, obesity (body mass index > 35 kg/m2), impaired renal and/or hepatic function
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Before induction of anesthesia, ramosetron 0.3 mg combined with low dose midazolam(75 microg/kg) is injected
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12612000757819